Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 41, 2010, Pages 17692-17697

  Carpintero, Rakel ^a   Brandt, Karim J ^a   Gruaz, Lyssia ^a   Molnarfi, Nicolas ^b   Lalive, Patrice H ^a,c   Burger, Danielle ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Copaxone; Immunomodulation; Inflammation; Multiple sclerosis; Signal transduction

Indexed keywords

GLATIRAMER; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MONOCYTES; MULTIPLE SCLEROSIS; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 78049273365     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009443107     Document Type: Article

References (54)

1. Burger D, Dayer JM (2000) Cytokine Reference, eds Oppenheim JJ, Feldmann M (Academic Press, London), pp 319-336.
2. Dinarello CA (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343:732-734.
3. Burger D, Dayer JM, Palmer G, Gabay C (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 20:879-896.
4. Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20-38.
5. Aksentijevich I, et al. (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426-2437.
6. Dinarello CA (2007) Mutations in cryopyrin: Bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum 56:2817-2822.
7. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435.
8. Badovinac V, Mostarica-Stojković M, Dinarello CA, Stosić-Grujicić S (1998) Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 85:87-95. (Pubitemid 28255441)
9. Furlan R, et al. (2007) HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 14:93-98.
10. Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y (2006) Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol 18:399-407.
11. Martin D, Near SL (1995) Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 61:241-245.
12. Acosta-Rodriguez EV, et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639-646.
13. Chung Y, et al. (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30:576-587.
14. Sela M, Teitelbaum D (2001) Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2:1149-1165. (Pubitemid 32633717)
15. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P (2001) Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: Effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 8:1196-1203.
16. Weber MS, et al. (2004) Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127:1370-1378.
17. Kim HJ, et al. (2004) Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172:7144-7153.
18. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML (2003) Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 170:4483-4488.
19. Jung S, et al. (2004) Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 148:63-73.
20. Stasiolek M, et al. (2006) Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129:1293-1305.
21. Hussien Y, Sanna A, Söderström M, Link H, Huang YM (2001) Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 121:102-110.
22. Liblau R (2009) Glatiramer acetate for the treatment of multiple sclerosis: Evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci 287(Suppl 1):S17-S23.
23. Kantengwa S, et al. (2007) Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol 185:123-129.
24. Zhang M, et al. (2000) Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 103:189-194. (Pubitemid 30079731)
25. Aharoni R, Sonego H, Brenner O, Eilam R, Arnon R (2007) The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 112:110-119.
26. Arnon R, Aharoni R (2004) Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 101(Suppl 2):14593-14598.
27. Sciacca FL, Canal N, Grimaldi LME (2000) Induction of IL-1 receptor antagonist by interferon beta: Implication for the treatment of multiple sclerosis. J Neurovirol 6 (Suppl 2):S33-S37.
28. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D (2001) IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 14:272-282.
29. Burger D, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 106:4355-4359.
30. Mikol DD, et al.; REGARD study group (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903-914.
31. Gutierrez EG, Banks WA, Kastin AJ (1994) Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 55:153-160.
32. Neuhaus O, Kieseier BC, Hartung HP (2007) Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 259:27-37. (Pubitemid 47031199)
33. Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D (2008) Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions. Mol Immunol 45:3419-3427.
34. Rehani K, Wang H, Garcia CA, Kinane DF, Martin M (2009) Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J Immunol 182:547-553.
35. Darragh J, Ananieva O, Courtney A, Elcombe S, Arthur JS (2010) MSK1 regulates the transcription of IL-1ra in response to TLR activation in macrophages. Biochem J 425:595-602.
36. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D (2005) The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 174:2974-2980. (Pubitemid 40279717)
37. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769-776.
38. Frame S, Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359:1-16.
39. Fridkis-Hareli M, et al. (1999) Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol 162:4697-4704.
40. Fridkis-Hareli M, et al. (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA 91:4872-4876.
41. Andreae S, Buisson S, Triebel F (2003) MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102:2130-2137. (Pubitemid 37122390)
42. Palkama T, Hurme M (1993) Signal transduction mechanisms of HLA-DR-mediated interleukin-1 beta production in human monocytes. Role of protein kinase C and tyrosine kinase activation. Hum Immunol 36:259-267.
43. Kriegel MA, et al. (2008) Anti-HLA-DR-triggered monocytes mediate in vitro T cell anergy. Int Immunol 20:601-613.
44. Palacios R (1985) Monoclonal antibodies against human Ia antigens stimulate monocytes to secrete interleukin 1. Proc Natl Acad Sci USA 82:6652-6656.
45. Palkama T, Sihvola M, Hurme M (1989) Induction of interleukin 1 alpha (IL-1 alpha) and IL-1 beta mRNA expression and cellular IL-1 production by anti-HLA-DR antibodies in human monocytes. Scand J Immunol 29:609-615.
46. Trede NS, Geha RS, Chatila T (1991) Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. J Immunol 146:2310-2315.
47. Weber MS, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13:935-943.
48. Stapulionis R, et al. (2008) Structural insight into the function of myelin basic protein as a ligand for integrin alpha M beta 2. J Immunol 180:3946-3956.
49. Rezzonico R, Chicheportiche R, Imbert V, Dayer JM (2000) Engagement of CD11b and CD11c beta2 integrin by antibodies or soluble CD23 induces IL-1beta production on primary human monocytes through mitogen-activated protein kinase-dependent pathways. Blood 95:3868-3877.
50. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 32:577-595.
51. Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777-784.
52. Molnarfi N, Gruaz L, Dayer JM, Burger D (2004) Opposite effects of IFN beta on cytokine homeostasis in LPS- and T cell contact-activated human monocytes. J Neuroimmunol 146:76-83. (Pubitemid 38032958)
53. Hyka N, et al. (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97:2381-2389.
54. Molnarfi N, Gruaz L, Dayer JM, Burger D (2007) Opposite regulation of IL-1beta and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccharides or contact with T cells. J Immunol 178:446-454.